Literature DB >> 17663753

Deciphering adaptor specificity in GFL-dependent RET-mediated proliferation and neurite outgrowth.

Jason A Gustin1, Mao Yang, Eugene M Johnson, Jeffrey Milbrandt.   

Abstract

Glial cell derived neurotrophic factor (GDNF)-dependent receptor tyrosine kinase RET activity is required for proper development of the nervous system and genitourinary tract. Loss-of-function mutations in RET are associated with enteric nervous system abnormalities (Hirschsprung disease) and renal deficits (Potter's syndrome), whereas activating mutations lead to hereditary cancer syndromes (multiple endocrine neoplasia type 2A and type 2B). RET activation is crucial for the proper regulation of a variety of cellular processes including cell migration, proliferation and neurite outgrowth. By analyzing a series of RET mutants we found that Y1062 was critical for stimulating GDNF-mediated proliferation as well as proliferation stimulated by GDNF-independent oncogenic forms of RET. Studies using small interfering RNA driven by lentivirus to knock-down expression of particular adaptor proteins that interact with RET phospho-Y1062, demonstrated that only Src-homology 2 and growth factor receptor binding protein 2 were necessary for RET-mediated proliferation by wild type and oncogenic forms of RET. Interestingly, we discovered that Y1062 was also required for GDNF-stimulated neurite outgrowth. However, small interfering RNAs to either Src-homology 2 or growth factor receptor binding protein 2 or a panel of other adaptor proteins known to interact with RET Y1062 were incapable of blocking GDNF-stimulated neurite formation, indicating that differential use of intracellular adaptors is responsible for regulating alternative RET-stimulated cellular events such as proliferation versus a differentiation response like neurite outgrowth.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17663753     DOI: 10.1111/j.1471-4159.2007.04624.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  6 in total

1.  Traditional and targeted exome sequencing reveals common, rare and novel functional deleterious variants in RET-signaling complex in a cohort of living US patients with urinary tract malformations.

Authors:  Rajshekhar Chatterjee; Enrique Ramos; Mary Hoffman; Jessica VanWinkle; Daniel R Martin; Thomas K Davis; Masato Hoshi; Stanley P Hmiel; Anne Beck; Keith Hruska; Doug Coplen; Helen Liapis; Robi Mitra; Todd Druley; Paul Austin; Sanjay Jain
Journal:  Hum Genet       Date:  2012-06-23       Impact factor: 4.132

2.  Sominone enhances neurite outgrowth and spatial memory mediated by the neurotrophic factor receptor, RET.

Authors:  Chihiro Tohda; Eri Joyashiki
Journal:  Br J Pharmacol       Date:  2009-07-08       Impact factor: 8.739

3.  Correlation between multiple RET mutations and severity of Hirschsprung's disease.

Authors:  Kunihiro Ishii; Takashi Doi; Ken Inoue; Manabu Okawada; Geoffrey J Lane; Atsuyuki Yamataka; Chihiro Akazawa
Journal:  Pediatr Surg Int       Date:  2013-02       Impact factor: 1.827

4.  Organotypic specificity of key RET adaptor-docking sites in the pathogenesis of neurocristopathies and renal malformations in mice.

Authors:  Sanjay Jain; Amanda Knoten; Masato Hoshi; Hongtao Wang; Bhupinder Vohra; Robert O Heuckeroth; Jeffrey Milbrandt
Journal:  J Clin Invest       Date:  2010-02-15       Impact factor: 14.808

5.  Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through polarity protein Par-3/atypical protein kinase C (aPKC) signaling.

Authors:  Bogdan Beirowski; Jason Gustin; Sean M Armour; Hiroyasu Yamamoto; Andreu Viader; Brian J North; Shaday Michán; Robert H Baloh; Judy P Golden; Robert E Schmidt; David A Sinclair; Johan Auwerx; Jeffrey Milbrandt
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

Review 6.  The GDNF Family: A Role in Cancer?

Authors:  Graeme C Fielder; Teresa Wen-Shan Yang; Mahalakshmi Razdan; Yan Li; Jun Lu; Jo K Perry; Peter E Lobie; Dong-Xu Liu
Journal:  Neoplasia       Date:  2017-12-12       Impact factor: 5.715

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.